Figure 8.

Oncolytic Efficacy of Ld0-GFP in Syngeneic HCC Mouse Models

(A) Treatment scheme. i.v., intravenous. (B) Growth of vehicle-, d0-GFP-, or Ld0-GFP-treated H22 tumors in immunocompetent BALB/c mice (n = 8). (C) Long-term survival of BALB/c mice bearing H22 tumors. (D) Long-term survival in orthotopic HCC model bearing mouse H22 HCC in situ, after receiving three i.v. treatments of Ld0-GFP (1 × 10⁷ PFU) or vehicle (n = 8). (E) Representative images of livers from each group on days 10 and 20 following virus i.v. injection. Dashed black lines represent tumor areas. The statistical significance of the intergroup comparisons of tumor volumes or body weight was analyzed using a repeated-measure ANOVA. Data for survival were analyzed by the log-rank (Mantel-Cox) test. All values are presented as the mean ± SEM. *p < 0.05, **p < 0.01; ns, not significant.